GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40698)

  • GC81839 structure
    GC81839Idescarpin
    CAS: 188557-53-1
    Purity: >93.00%

    Idescarpin is a phenolic glycoside compound isolated from Idesia polycarpa and exhibits an extremely bitter taste.

  • GC81840 structure
    GC81840INF7TAT acetate
    Purity: >98.00%

    INF7TAT acetate is an amphipathic cell-penetrating peptide that mediates intracellular delivery of CRISPR ribonucleoproteins.

  • GC81842 structure
    GC81842Lck Inhibitor III free base
    CAS: 918870-44-7
    Purity: >98.00%

    Lck Inhibitor III free base is a Lck inhibitor with an IC 50 of 867 nM.

  • GC81843 structure
    GC81843Lumipodlin
    CAS: 2368183-94-0
    Purity: >98.00%

    Lumipodlin is a programmed cell death ligand 1 ( PD-L1 ) inhibitor.

  • GC81844 structure
    GC81844N-Methyl pemetrexed disodium
    Purity: >98.00%

    N-Methyl pemetrexed disodium is an impurity of Pemetrexed.

  • GC81845 structure
    GC81845Melimine acetate
    Purity: >98.00%

    Melimine acetate is an antimicrobial peptide with broad-spectrum antimicrobial activity against Gram-negative/Gram-positive bacteria, fungi and protozoa.

  • GC81846 structure
    GC81846Nivitol
    CAS: 869743-37-3
    Purity: >98.00%

    Nivitol (UP302) is a natural phenolic compound discovered from Dianella ensifolia and also acts as a Tyrosinase inhibitor.

  • GC81848 structure
    GC81848Noratropine
    CAS: 16839-98-8
    Purity: >98.00%

    Noratropine is a major metabolite of Atropine.

  • GC81849 structure
    GC81849NOTA-DPI-4452 TFA
    Purity: >98.00%

    NOTA-DPI-4452 TFA is a trifluoroacetate derivative with DPI-4452 as the parent peptide.

  • GC81850 structure
    GC81850p53 Bipartite NLS TFA
    Purity: >98.00%

    p53 Bipartite NLS TFA is a bipartite nuclear localization signal derived from p53.

  • GC81851 structure
    GC81851Pancreatic Polypeptide, rat TFA
    Purity: >98.00%

    Pancreatic Polypeptide, rat TFA (Rat pancreatic polypeptide TFA) is a rat-derived Pancreatic Polypeptide.

  • GC81852 structure
    GC81852Piezo1 agonist 2 hydrochloride
    Purity: >98.50%

    Piezo1 agonist 2 hydrochloride is a blood-brain barrier-permeable Piezo1 agonist and Jedi2 conjugate that utilizes LAT1.

  • GC81854 structure
    GC81854Pyrazinamide-¹⁵N,d₃
    CAS: 1246817-81-1
    Purity: >98.00%

    Pyrazinamide - 15 N,d 3 (Pyrazinecarboxamide- 15 N,d 3 ) is the deuterated, 15 N-labeled Pyrazinamide.

  • GC81855 structure
    GC81855(R)-RXFP2 agonist 2
    CAS: 3123585-08-7
    Purity: >98.00%

    (R)-RXFP2 agonist 2 is the R-type isomer of RXFP2 agonist 2.

  • GC81857 structure
    GC81857Sulbactam-d₂
    CAS: 77741-83-4
    Purity: >98.00%

    Sulbactam -d 2 (CP45899-d 2 ) is the deuterated-labeled Sulbactam.

  • GC81858 structure
    GC81858SuO-Glu-Val-Cit-PAB-MMAE-d₈-1
    Purity: >95.50%

    SuO-Glu-Val-Cit-PAB-MMAE -d 8 -1 (NHS-Glutarate-Val-Cit-PAB-MMAE-d 8 -1) is the deuterated-labeled SuO-Glu-Val-Cit-PAB-MMAE.

  • GC81859 structure
    GC81859TH-Z827 diTFA
    Purity: >98.00%

    TH-Z827 diTFA is a selective KRAS G12D inhibitor that exhibits activity against GDP-bound and GMPPNP-bound KRAS G12D, but shows no activity against KRAS (WT) and KRAS G12C.

  • GC81860 structure
    GC81860UBA6-IN-1 hydrochloride
    CAS: 1557138-61-0
    Purity: >98.00%

    UBA6-IN-1 hydrochloride is a UBA6/UBE1L2 inhibitor ( IC 50 ≤50 nM) that acts by reducing the level of squalene epoxidase ( SQLE ).

  • GC81861 structure
    GC81861Vancomycin-d₁₀ acetate
    Purity: >98.00%

    Vancomycin-d 10 acetate is the deuterated-labeled Vancomycin acetate.

  • GC81862 structure
    GC81862YJ1206 TFA
    Purity: >98.00%

    YJ1206 TFA is an orally active selective CDK12 / CDK13 PROTAC degrader.

  • GC81863 structure
    GC818632A/2B Dengue protease substrate acetate
    Purity: >98.00%

    2A/2B Dengue protease substrate (Ac-RTSKKR-pNA) acetate is a peptide substrate for the Dengue NS2B-NS3 protease, with a K i value of 12 μM.

  • GC81864 structure
    GC818643BP-3580 TFA
    Purity: >98.00%

    3BP-3580 TFA (compound 11) is a conjugate targeting FAP that binds to FAP-positive cells via the FAPI moiety and internalizes, delivering the payload to FAP -expressing cells, thereby inhibiting RA FLS proliferation, migration, and invasion, reducing inflammatory cytokine expression, and suppressing pannus formation.

  • GC81865 structure
    GC81865(7S)-Nivegacetor
    CAS: 2443491-73-2
    Purity: >98.00%

    (7S)-Nivegacetor ((7S)-RG6289) is an isomer of Nivegacetor.

  • GC81866 structure
    GC818668-Azidooctan-1-amine
    CAS: 867338-63-4
    Purity: >98.00%

    8-Azidooctan-1-amine is a PROTAC linker that can be used in PROTAC synthesis-related research, such as L013 [1] .